Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey.

OBJECTIVE Risperidone is a promising agent for the treatment of schizophrenia, Tourette's disorder, mood disorders, and disruptive behavior disorders in young populations. However, adverse effects of risperidone may take a long time to emerge. The objective of this study was to investigate the changes in the liver function tests (LFTs) associated with more than 6 months of risperidone treatment in children and adolescents. METHOD A total of 102 youths treated with risperidone for more than 6 months were eligible for the study. For this study, patients' baseline and follow-up weight and hepatobiliary function tests, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), and serum bilirubin levels, were measured at baseline and at 6 months. RESULTS Asymptomatic abnormalities of LFTs, mostly ALP elevation, were found in 38.2% of the cases, and marked elevation of liver enzymes was found in 0.8% of cases treated with risperidone. The mean levels of liver enzymes and bilirubin of the patients were significantly higher than the baseline after first and sixth months of treatment. However, there was no statistically significant change in the liver enzymes and bilirubin levels between the first and sixth months. There was no significant relationship between changes in weight and liver enzymes and bilirubin levels after 6 months of risperidone treatment. CONCLUSION These findings suggest that risperidone treatment in the long term commonly leads to liver function changes, although at therapeutic doses in children and adolescents it may rarely induce a serious hepatic toxicity. Concomitant use of antidepressants and methylphenidate and variations in age and pubertal status are limitations of present study. Further studies are needed to assess the importance and role of other variables over LFT abnormalities in youth population.

[1]  Barbara Napolitano,et al.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. , 2009, JAMA.

[2]  H. Ankarali,et al.  Risperidone and liver function tests in children and adolescents: A short-term prospective study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[3]  N. Atasoy,et al.  A review of liver function tests during treatment with atypical antipsychotic drugs: A chart review study , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  T. Obata.  Intrahepatic cholestasis and hyperbilirubinemia in ethynyl estradiol and chlorpromazine-treated rats , 1983, Gastroenterologia Japonica.

[5]  A. Schatzberg.  Safety and tolerability of antidepressants: weighing the impact on treatment decisions. , 2007, The Journal of clinical psychiatry.

[6]  B. Herpertz-Dahlmann,et al.  Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents , 2007, Journal of Neural Transmission.

[7]  J. Swanson,et al.  Safety and tolerability of methylphenidate in preschool children with ADHD. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[8]  C. McDougle,et al.  Acute and long-term safety and tolerability of risperidone in children with autism. , 2005, Journal of child and adolescent psychopharmacology.

[9]  C. Prats,et al.  Acute Cholestatic Hepatitis Probably Associated with Risperidone , 2005 .

[10]  Soo-Jung Lee,et al.  Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone , 2005, International clinical psychopharmacology.

[11]  I. Smith,et al.  Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders , 2004, Pediatrics.

[12]  D. Safer.  A Comparison of Risperidone-Induced Weight Gain Across the Age Span , 2004, Journal of clinical psychopharmacology.

[13]  R. Findling,et al.  Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. , 2004, The American journal of psychiatry.

[14]  A. Serretti,et al.  New antipsychotics and schizophrenia: a review on efficacy and side effects. , 2004, Current medicinal chemistry.

[15]  J. Lieberman,et al.  A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial , 2004, Neuropsychopharmacology.

[16]  M. Schmidt,et al.  Risperidone-associated steatohepatitis and excessive weight-gain. , 2004, Pharmacopsychiatry.

[17]  T. Wilens,et al.  Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[18]  P. Brovedani,et al.  A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. , 2003, The Journal of clinical psychiatry.

[19]  J. Vázquez-Barquero,et al.  Alterations of liver function test in patients treated with antipsychotics , 2003, Journal of clinical laboratory analysis.

[20]  D. Januel,et al.  Liver function tests during treatment with antipsychotic drugs A case series of 23 patients , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  D. Januel,et al.  Tolérance hépatique des antipsychotiques atypiques. , 2002 .

[22]  C. Binder,et al.  Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. , 2002, Pediatrics.

[23]  C. McDougle,et al.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[24]  R. Weizman,et al.  Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[25]  S. Kuperman,et al.  Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[26]  G. Maislin,et al.  Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[27]  J. George,et al.  Hepatotoxicity of Commonly Used Drugs: Nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs , 2002, Seminars in liver disease.

[28]  I. Gaertner,et al.  Relevance of Liver Enzyme Elevations With Four Different Neuroleptics: A Retrospective Review of 7,263 Treatment Courses , 2001, Journal of clinical psychopharmacology.

[29]  E. Hahn,et al.  Risperidone-induced cholestatic hepatitis. , 2001, European journal of gastroenterology & hepatology.

[30]  M. Tohen,et al.  A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. , 2001, Journal of child and adolescent psychopharmacology.

[31]  M. Schluchter,et al.  A double-blind pilot study of risperidone in the treatment of conduct disorder. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[32]  D. Cicchetti,et al.  Risperidone-associated weight gain in children and adolescents: a retrospective chart review. , 2000, Journal of child and adolescent psychopharmacology.

[33]  P. Muglia,et al.  Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. , 2000, Journal of child and adolescent psychopharmacology.

[34]  W. Fleischhacker,et al.  Transient increase of liver enzymes induced by risperidone: two case reports. , 1999, Journal of clinical psychopharmacology.

[35]  T. Erselcan,et al.  Effect of Antiepileptic Drugs on Bone Mineral Density in Children Between Ages 6 and 2 Years , 1999, Clinical pediatrics.

[36]  M. Wiznitzer,et al.  Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. , 1999, Journal of child and adolescent psychopharmacology.

[37]  N. Ryan,et al.  IS LIVER FUNCTION MONITORING WARRANTED DURING RISPERIDONE TREATMENT , 1998 .

[38]  R. Conley,et al.  Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. , 1998, Journal of child and adolescent psychopharmacology.

[39]  H. Steiner,et al.  Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. American Academy of Child and Adolescent Psychiatry. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[40]  S. Kumra,et al.  Case study: risperidone-induced hepatotoxicity in pediatric patients. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[41]  H. Greene,et al.  Steatohepatitis in obese children: a cause of chronic liver dysfunction. , 1983, The American journal of gastroenterology.

[42]  H. Dincsoy,et al.  Haloperidol-induced chronic cholestatic liver disease. , 1982, Gastroenterology.